Restenosis in drug-eluting stents (DESs) occurs infrequently, however, it remains a pervasive clinical problem. We interrogated our autopsy registry to determine the underlying mechanisms of DES restenosis, and further we investigated the neointimal characteristics of DESs and compared with bare metal stents (BMSs).
Introduction
While drug-eluting stents (DESs) reduce the incidence of restenosis compared with bare metal stents (BMSs), they do not eliminate it. Given the large number of percutaneous coronary intervention procedures, even a low incidence of restenosis translates into a significant absolute number of patients undergoing repeat revascularization after DES implantation. Many factors including patient demographics, lesion characteristics, interventional procedural details, and others have been reported as predictors for DES restenosis from clinical studies, however, only few studies evaluated the histopathology of DES restenosis. Further, a steady increase in target lesion revascularization has been reported in clinical trials in long-term DES implants, 1,2 suggesting unique neointimal remodelling process different from BMSs. Not only delayed healing, 3 but also type of neointimal growth with a greater potential risk for neoatherosclerosis is thought to play a role for the needs of repeat revascularization, 4 however, the pathology of neointimal characteristics is not fully understood.
Therefore, the present study was designed (i) to investigate the histomorphological predictors of restenosis in DESs and (ii) to determine the neointimal characteristics of DESs, using human autopsy hearts retrieved from patients following stents implantation.
Methods Lesion selection and histology processing
Lesions with DES implants were reviewed from our autopsy registry of human hearts obtained in diagnostic consultation during years from 2005 to 2011 ( Figure 1) . Stents with implant duration ≥30 days were selected for the analysis of histomorphological factors related to DES restenosis. Because we sought to investigate the parameters to differentiate 'well-healed' non-restenotic lesions from restenotic or occluded lesions, lesions with thrombosis, hypersensitivity reaction, and unhealed struts (the ratio of uncovered to total struts .30%) were excluded from the analysis. 5, 6 Lesions including Endeavorw stent (Medtronic, Minneapolis, MN, USA) were excluded since clinical studies have shown significantly higher restenosis rates when compared with other commercially used DESs. Finally, a total of 65 patients with 82 lesions with one or more DESs [sirolimus-(SES), paclitaxel-(PES), or everolimus-eluting stents (EES)] were examined.
The stented arteries obtained at autopsy were processed as previously described. 3 The stented artery was segmented at 3-mm intervals and stained with haematoxylin and eosin (H&E) and modified Movat pentachrome, and a total of 785 cross-sections of coronary arteries were histologically reviewed.
Histomorphological assessment of factors associated with restenosis/occlusion in drug-eluting stents
The type of underlying plaque was classified according to the modified AHA classification. 7 The degree of calcification was defined as none, minimal (micro-calcification), mild (,1-eighth circumferential arc), moderate (1-eighth to one quadrant circumferential arc), or severe (≥1 quadrant circumferential arc). The measurements of external elastic lamina (EEL), stent, and lumen area were determined by the morphometric software (IP Lab for Mac OS X, Scanalytics, Rockville, MD, USA). According to the section with the severest cross-sectional area stenosis inside the stented segment, the lesions were categorized into four groups: (i) patent (,50% stenosis), (ii) intermediate (50 -74% stenosis), (iii) restenosis (≥75% but with residual lumen), or (iv) total occlusion (in-stent area occupied by organized thrombus, proteoglycan matrix with microcapillaries) ( Figure 2 ). Other parameters were measured in segments with the severest stenosis, or in those with total occlusion, the middle section was utilized ( Figure 2) for determining: neointimal thickness, underlying plaque eccentricity index ¼ maximum/minimum thickness of underlying plaque, and normalized inter-strut distance ¼ maximum/mean inter-strut distance per section. The presence of fibrin, inflammation (.10 inflammatory cells), neoangiogenesis, and haemorrhage around each strut was evaluated. 5 Medial disruption and stent strut penetration into the necrotic core were also assessed as previously described. 8 
Comparison of neointimal characteristics in restenotic lesions in drug-eluting stents vs. bare metal stents
To investigate vascular remodelling after stenting with DES, DES lesions with restenosis were selected. For comparison, restenotic BMSs of similar implant duration were selected from the BMS registry ( Figure 1) . Sections with the severest % stenosis were additionally stained by picrosirius red, alcian blue, and immunohistochemistry [a-smooth muscle actin (a-SMA), CD68/KP-1, CD45RO/UCHL-1] for the detection of collagen, proteoglycan-rich extracellular matrix (ECM), smooth muscle cell (SMC), macrophages, and T-lymphocyte. 8 -10 In limited cases, we stained both BMSs and DESs for endothelialization (CD31/34). For the details of neointimal component analysis, see Supplementary material online, Method.
Statistical analysis
Values were expressed as means + SD. Normality of distribution was tested with the Wilk-Shapiro test. Statistical comparisons of normally distributed measurements were performed by linear generalized estimating equation modelling with an assumed Gaussian distribution, an identity link function, and an assumed exchangeable structure for the within-cluster correlation matrix in consideration of the clustered nature of ≥1 individual measurements from one patient. Generalized estimating equation with an assumed binominal family distribution, a logistic link function, and an exchangeable structure in the correlation matrix was used to assess binominal data. For the comparison of nonnormally distributed data, the Kruskal -Wallis test was used. Categorical data was analysed by Pearson's x 2 test or Fisher's exact test. All analyses were performed with the SPSS software (version 19; Chicago, IL, USA) and JMP5 (SAS Institute, Cary, NC, USA). All reported P-values were determined by two-sided analysis and values of ,0.05 were regarded as statistically significant.
Results

Patient/lesion characteristics
According to the degree of the severest cross-sectional area stenosis, DES lesions were classified: patent (,50%, n ¼ 28), intermediate (50 -74%, n ¼ 25), restenosis (≥75% with residual lumen, n ¼ 19), or total occlusion (n ¼ 10). The neointima in patent, intermediate, and restenotic DES stents consisted mainly of SMCs in a proteoglycan-collagen matrix while the in-stent area of total occlusion consisted of an organized thrombus showing a low smooth muscle cellularity within proteoglycan matrix with micro-capillaries in the presence or absence of inflammation ( Figure 2) .
Overall, there were no significant differences in age, gender, medical history, and indication for stent implantation between groups ( Table 1) . Restenotic and total occluded stents were located predominantly in mid-and distal/branches of the coronary arteries (77 and 90%, respectively) while only 54% of patent stents were placed in these regions (P ¼ 0.033).
Morphometric analysis
There were no significant differences in overall underlying plaque morphology among all groups ( Table 2 ). The total length of stented segment was longer in restenotic (26.7 + 14.0 mm) and occluded (25.7 + 8.9 mm) stents, followed by intermediate (23.5 + 10.7 mm), and patent groups (17.3 + 8.2 mm) (P ¼ 0.034, Table 3 ). The length of stenosis (≥75% cross-sectional lumen narrowing) within the stents was mostly focal [17 of 19 (89%)] in the restenotic DESs (4.2 + 1.9 mm, length) while in the occluded DES 80% were of the diffuse type (17.0 + 7.1 mm, length). The location of focal stenosis in the restenotic DES was predominantly at the proximal or distal portion of the stented segment (Supplementary material online, Figure S1 ). The stented area was smaller in the occluded group (4.6 + 1.6 mm 2 ) when compared with restenotic (5.7 + 1.9 mm 2 ), intermediate (5.3 + 2.1 mm 2 ), and patent group (5.9 + 2.1 mm 2 ), but the differences were not statistically significant (P ¼ 0.33) ( Table 3) . The maximum inter-strut distance was the highest in restenosis, followed by occlusion, intermediate, and the least in the patent group even after normalization (normalized maximum inter-strut distance 1.87 + 0.55, 1.65 + 0.33, 1.60 + 0.22, and 1.50 + 0.21, respectively, P ¼ 0.011). There was a weak but significant positive correlation between neointimal thickness and maximum inter-strut distance (r ¼ 0.446, P , 0.001) ( Figure 3 ).
Histopathological features associated with drug-eluting stent restenosis and occlusion
The impact of strut penetration into the necrotic core and medial disruption on neointimal growth in DESs was evaluated because these features have been reported to be the predictors of restenosis in BMSs. 8 The incidence of strut penetration into the necrotic core was similar among groups (patent: 17%, intermediate: 14%, restenosis: 6%, occlusion: 10%, P ¼ 0.61). Neointimal thickness was lower in sections with core penetration (0.27 + 0.13 mm) than in those without core penetration (0.42 + 0.27 mm) (P ¼ 0.13). Figure 4 ). There was a trend towards greater neointimal thickness in sections with medial disruption (0.47 + 0.26 mm) than in those without medial disruption (0.38 + 0.28 mm) (P ¼ 0.060). Further, neointimal thickness correlated with maximum inter-strut distance more robustly in the presence of medial disruption (r ¼ 0.678, P , 0.001) than in the absence of medial disruption (r ¼ 0.332, P ¼ 0.11) (Figure 3 ), suggesting that the combination of medial disruption and uneven strut distribution that results in uneven drug distribution leads to greater neointimal growth. We did not observe any differences by stent type (SES, PES, and EES).
Histomorphological predictors for drug-eluting stents restenosis and occlusion
Multivariate logistic analysis comparing patent vs. restenosis or occlusion groups demonstrated normalized maximum inter-strut distance as a predictor of restenosis [odds ratio (OR) 17.4, P ¼ 0.039] and medial tear length as a trigger for occlusion (medial tear length, OR: 5.11, P ¼ 0.033) while greater total length of stented segment was also a common indicator of both restenosis and occlusion in DES ( Table 5 ). We further evaluated the influences of underlying plaque morphology on inter-strut distance and medial disruption (Supplementary material online, Result, Figures S2 and S3) . In brief, the presence of severe calcification was associated with greater separation of struts; and medial disruption was more frequently observed in eccentric plaques. The cellular composition near the lumen mainly consisted of SMCs; DESs showed significantly lower cellularity than BMSs (900 + 369 vs. 1358 + 499 cells/mm 2 , respectively, P ¼ 0.006) ( Table 6 and Figure 5 ). The collagen content (as assessed by picrosirus stains) was relatively lower in DESs (23.0 + 15.4%) compared with BMS (33.7 + 18.3%) (P ¼ 0.075) with the latter showing more advanced feature (collagen score: DESs: 1.0 + 0.4, BMSs: 1.4 + 0.4, P ¼ 0.012) ( Table 6) . Conversely, the % proteoglycan-rich ECM (alcian blue stain) was greater in DESs (50.7 + 20.5%) when compared with BMSs (33.8 + 22.0%) (P ¼ 0.032). The temporal changes of aforementioned parameters are summarized in bar graphs in Figure 5 . The increase in collagen and decrease in the proteoglycanrich ECM occurred over time in both stent groups, however, the healing process is delayed in DESs when compared with BMSs. The number of the SMC close to the lumen peaked at 1-2 years and then decreased in BMSs, whereas in DESs there was no appreciable change noted over the same period. Inflammation was further evaluated in the area around stent strut, and the results are summarized in Supplementary material online, Table and Figure S4 . In brief, macrophage and T-lymphocyte infiltration accompanied by neoangiogenesis were observed in both stent groups, with a trend towards a greater number of cells observed in BMSs than DESs. We performed correlation between macrophage density and neointimal thickness for both DESs and BMSs and showed a significant correlation between BMS neointimal thickness and macrophage infiltration (r ¼ 0.73, P ¼ 0.02), but no such correlation was observed for DES (see Supplementary material online, Figure S4B ). No correlation was observed for T-lymphocytes and neointimal thickness in either stents.
Neointimal characteristics of restenotic drug-eluting stents and bare metal stents
Discussion
The present autopsy study comprehensively investigated the underlying mechanisms and the histopathological characteristics of DES restenosis, utilizing human autopsy coronary arteries, and the results yielded several novel findings from the view of histopathology. On the basis of pathological findings, we have shown that there are likely differences between the underlying aetiologies of DES restenosis and those of DES occlusion. The presence of medial injury, known as a potent inducer of restenosis in BMS, per se was not the primary predictor of restenosis in the setting of DES. Rather, uneven distribution of an anti-proliferative drug, as identified by greater maximum inter-strut distance (OR: 17.4, P ¼ 0.04), was associated with restenosis in DESs. However, inadequate antiproliferative drug concentration as the underlying mechanism of restenosis will require further study to prove this hypothesis generating finding in the current pathology study. On the other hand, occlusion of DES ensues more likely when the ballooning or stenting causes extensive vessel injury with greater tearing of the media, (medial tear length, OR: 5.11, P ¼ 0.03) irrespective of drug distribution. Also, stent length was an important predictor of restenosis and occlusion (OR: 1.07, P ¼ 0.035; 1.41, P ¼ 0.039, respectively). However, no differences were observed between different stents (SES, PES, and EES).
Impacts of drug distribution and vessel injury on drug-eluting stents restenosis and occlusion
Local gradient of stent-based drug delivery has been implicated as an important factor of neointimal growth or vascular healing by computational simulation and animal models. 11 A clinical study utilizing intravascular ultrasound (IVUS) confirmed this notion by demonstrating a larger maximum inter-strut angle at a minimum lumen site of restenotic SES when compared with that of non-restenotic SES (135 + 398 vs. 97 + 298, P , 0.01). 12 It has been also reported that uncovered struts and stent thrombosis were seen mainly in mid-portion of the stented segment, reflecting longitudinal drug gradient along the stent length and its effect on neointimal suppression. 5 The present study demonstrated that greater separation of struts correlated with greater neointimal growth and that restenosis tended to occur at proximal and distal portion of the stented segment, suggesting that inadequate drug delivery due to greater inter-strut distance (OR: 17.4, P ¼ 0.04) at restenosis sites may be the main cause of neointimal overgrowth in DESs. However, stent length was also a predictor of restenosis in DES. Factors such as the influence of diabetes, small vessel stenting, location of stent near branch points, and other unknown causes may also influence the presence of restenosis. Our findings nevertheless explain the focal nature of restenosis in DESs vs. BMSs.
Arterial wall injury is suggested to be a strong contributor to the neointimal growth or occurrence of restenosis within stents. A preclinical study in porcine coronary arteries reported that the severity of vessel injury from stenting strongly correlated with neointimal thickness and per cent diameter stenosis. 13 An autopsy study of the human coronary artery with BMS implantation confirmed a similar response, which showed that the presence of medial wall injury resulted in in-stent restenosis or occlusion with increase in inflammation and neoangiogenesis co-localized at the site of the vessel injury. 8 The increased release of biological mediators such as monocyte chemotactic protein-1 and vascular endothelial growth factor subsequent to medial damage is implicated as underlying mechanisms. 14, 15 The current histological study of DES identified a high incidence of media disruption (45% of 82 stented lesions) at the site of severe luminal narrowing within the stent. Drug-eluting stents showed less neointimal thickness in the presence and absence of media disruption [disruption (+): 0.47 + 0.26 mm vs. disruption (2): 0.38 + 0.28 mm] when compared with those of BMSs in a previous autopsy report [disruption (+): 0.79 + 0.29 mm vs. disruption (2): 0.61 + 0.31 mm]; 8 this difference between DESs and BMSs is secondary to the beneficial effects of anti-inflammatory and antiproliferative drug used on DESs. However, it appears that the efficacy of drugs wanes when the strut distribution is uneven (Figure 3) or when medial tear is extensive (Figure 4) . We also report similar macrophage infiltration in DESs and BMSs; however, in BMS the macrophage infiltration correlated with neointimal thickness (r ¼ 0.73, P ¼ 0.02) but not in DESs. Because macrophage infiltration in DESs does not lead to increased neointimal thickening, therefore drugs may suppress growth factor release in DES. The diffuse occlusion from thrombosis in DESs could be in part explained by augmented coagulation following excessive medial injury, likely with release of tissue factor during injury.
Neointimal characteristics and remodelling following drug-eluting stents implantation
We further investigated the neointimal characteristics of DESs in long-term vs. shorter implants. A histopathological study of human coronary BMS showed temporal changes of neointimal compositions, in which neointima up to 18 months remains hypercellular and rich in proteoglycan versican, hyaluronan, and type III collagen, and thereafter the staining for type I collagen becomes stronger with a decrease in cellularity and aforementioned ECM, indicating that remodelling of the neointima in BMSs is complete by 18 months to 2 years. 9 Our current study illustrated a similar time course of SMC density, i.e. it peaks at 1-2 years and then decreases in BMSs, whereas in DESs there is less cellularity with no remarkable change over time. This disparity might be related to neointimal behaviour over-time as reported in clinical studies of BMSs and DESs: late neointimal regression with luminal enlargement in BMSs 16 vs. continuous growth of neointima, referred to as 'late catch-up' phenomenon in DESs. 17, 18 Besides neointimal SMC, the ECM also plays an important role in vascular remodelling following stenting. The 'response-to-retention' hypothesis has been advocated by investigators claiming that the retention of lipoprotein associated with ECM such as proteoglycans is the initiating event of early atherogenic process in the native artery. 19 The incidence of new atherosclerotic change within stent (neoatherosclerosis) was documented in an autopsy study where neoatherosclerosis in DESs was shown to occur earlier than BMSs. 20 Although the delayed re-endothelialization, associated with enhanced permeability of plasma lipoproteins, is suggested as the most likely mechanism of accelerated neoatherosclerosis, greater ECM accumulation in DESs is another likely contributor to the promotion of neoatherosclerosis through ionic binding between lipoproteins and proteoglycans. 21, 22 Here, we show that endothelialization at least by CD 31/34 staining is observed in both DESs and BMSs restenotic lesions; however, it is not possible to demonstrate intercellular junction competency as it requires the need to study other molecules involved such as VE-cadherin and PECAM-1. It has also been implicated that lipoprotein retention, rather than increased influx, is a major determinant of atherosclerosis susceptibility in a study of transgenic mice expressing proteoglycan-binding-defective LDL. 23 The results of these studies and our study collectively suggest that the control of ECM modification could also be a potential target for new devices to improve long-term outcomes. For example, structural changes in the glycosaminoglycan chain of proteoglycans produced by cDNA-transduced SMC showed a resistance to atherogenesis by inhibiting lipid deposition and macrophage accumulation. 24 
Study limitations
As this is an autopsy study, the results may not be representative of persons who receive stents and survive without morbidity. Plastic (MMA) embedding was needed for the histological processing of stented coronary arteries, which limited our ability to use wider range of stains that could be performed by immunohistochemistry. Because of the difficulty in obtaining human autopsy samples, the study was performed in a limited number of cases, especially for total occlusion lesions. Therefore, the potential differences among various stent types could not be assessed and the ability to state with certainty that medial disruption is a predictor of occlusion cannot be made. Further studies are required to confirm the significance and application of our findings in a larger cohort.
Conclusions
Our autopsy study highlighted the importance of optimal drug delivery and decreased vessel injury for reduction in restenosis and occlusion in DES, respectively. Moreover, the histopathological difference in neointimal characteristics and remodelling process between DES and BMS may also explain the adverse events in DES in the long-term follow-up, which could be improved by further innovations in interventional technology.
